Prognostic Factors of Malignant Pheochromocytoma and Paraganglioma: A Combined SEER and TCGA Databases Review.


Journal

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
ISSN: 1439-4286
Titre abrégé: Horm Metab Res
Pays: Germany
ID NLM: 0177722

Informations de publication

Date de publication:
Jul 2019
Historique:
pubmed: 29 3 2019
medline: 20 12 2019
entrez: 29 3 2019
Statut: ppublish

Résumé

Pheochromocytoma (PCC) and paraganglioma (PGL) are rare malignancies while pathogenesis is strongly influenced by genetics. The prognostic factors of these patients remain poorly defined. We aim to study the epidemiology and survival pattern by analyzing the combination of SEER and Cancer Genome Atlas (TCGA) database. Primary outcome was overall survival (OS) and disease specific survival (DSS). Between 1973 and 2013, a total of 1014 patients with PGL or PCC were analyzed. Younger age and female were associated with better outcomes. The incidence of second primary malignancy in PGL/PCC patients was about 14.6%. This population had a significant longer DSS. Other factors, including surgical resection and origin from of aortic/carotid bodies, conferred remarkable survival advantage. In contrast, distant spread portended worse prognosis. Laterality, race, positive serum catecholamine marker did not demonstrate a significant association with OS and DSS. By analyzing TCGA database with total 184 patients were identified. Eighty out of 184 patients (43.5%) had at least one pathogenic mutation. Female had higher ratio of pathogenic mutations than male (58.7% vs. 41.3%) and

Identifiants

pubmed: 30919391
doi: 10.1055/a-0851-3275
doi:

Substances chimiques

Catecholamines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

451-457

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Lin Mei (L)

Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.

Arushi Khurana (A)

Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.

Taha Al-Juhaishi (T)

Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.

Anthony Faber (A)

Philips Institute for Oral Health Research, Virginia Commonwealth University, Richmond, Virginia, USA.

Francesco Celi (F)

Department of Endocrinology and Metabolism, Virginia Commonwealth University, Richmond, Virginia, USA.

Steven Smith (S)

Department of Pathology, Virginia Commonwealth University, Richmond, Virginia, USA.

Sosipatros Boikos (S)

Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH